"Another sector where a number of companies may see shares double is the biopharmaceutical arena. Especially watch companies like MannKind Corp. (MNKD), where insiders are heavily invested. MNKD is a development stage biopharmaceutical company which engages in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. This would be nothing more than a roll-of-the dice speculative stock if it weren't for one significant fact. The CEO and principal stockholder Alfred Mann has been buying the stock hand-over-fist. Mr. Mann purchased an additional $103 million worth of MNKD in December 2012. He now owns a total of more than 75.5 million shares worth over $188 million at current price levels .

If MNKD's most promising product candidate, Afrezza, gets FDA approval, the company may be gobbled up by a larger competitor or double on a myriad of speculative possibilities. Afrezza, an ultra-rapid-acting insulin treatment for adults with type 1 or type 2 diabetes has submitted its third application to the FDA requesting approval.

Keep in mind that any stock below $5-per-share is still considered a "penny stock" and very speculative. Most won't do well, but history indicates that about 1-in-10, when carefully screened, will produce spectacular results. When you're hoping for a "double" or more as your reward, never forget that this means you're willing to take at least double the risk. Only use speculative money that you can afford to lose with companies like JMBA, MNKD, ATADF and AXU."

http://seekingalpha.com/article/1111621-identifying-stocks-that-may-double-within-a-year